Gustavo Olvera-García1, Enrique Espinosa, Scott F Sieg, Michael M Lederman. 1. aDepartment of Research in Immunology, National Institute for Respiratory Diseases (INER), Mexico bDepartment of Medicine, Division of Infectious Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Abstract
OBJECTIVE: Despite the strong correlation of T-cell CD38 expression with HIV disease progression, evidence linking CD38 expression and dysfunction at the single cell level is scant. Since CD38⁺ memory CD4⁺ T cells, especially those from HIV-infected persons, fail to induce CD154 (CD40L) while responding to a superantigen with interferon (IFN)-γ or interleukin (IL)-2, we aimed to determine if recall responses to cytomegalovirus (CMV) were similarly affected in the CD38⁺ memory CD4⁺ T-cell subpopulation. DESIGN AND METHODS: Peripheral blood mononuclear cells from HIV+ patients and healthy controls were incubated 14 h with CMV antigens, the superantigen Staphylococcus aureus enterotoxin B or medium, and labeled for identification of central memory (T(CM)) and effector memory (T(EM)) CD4⁺ T cells, and for the intracellular detection of induced CD154, IFN-γ and/or IL-2 by flow cytometry. RESULTS: Compared with CD38⁻ cells, CD38⁺ T(CM) cells from patients had less CD40L induction after CMV stimulation, and increased IFN-γ response. Patients' CD38⁺ T(EM) cells showed a lower IL-2 response, and tended to have a greater IFN-γ response, in which CD154 induction frequently failed. CMV-specific responses of patients' CD38⁺ T(CM) and T(EM) cells were dominated by IFN-γ, and almost all IL-2⁺ cells co-expressed IFN-γ. IL-2 responses to the polyclonal activator S. aureus enterotoxin B were also significantly less frequent among CD38⁺ T(CM) and T(EM) cells than in CD38⁻ cells. CONCLUSION: Patients' CD38⁺ memory CD4⁺T-cell responses to CMV favor the effector cytokine IFN-γ over IL-2, in the context of deficient CD154 induction, which may limit co-stimulation, proliferation and survival.
OBJECTIVE: Despite the strong correlation of T-cell CD38 expression with HIV disease progression, evidence linking CD38 expression and dysfunction at the single cell level is scant. Since CD38⁺ memory CD4⁺ T cells, especially those from HIV-infectedpersons, fail to induce CD154 (CD40L) while responding to a superantigen with interferon (IFN)-γ or interleukin (IL)-2, we aimed to determine if recall responses to cytomegalovirus (CMV) were similarly affected in the CD38⁺ memory CD4⁺ T-cell subpopulation. DESIGN AND METHODS: Peripheral blood mononuclear cells from HIV+ patients and healthy controls were incubated 14 h with CMV antigens, the superantigen Staphylococcus aureus enterotoxin B or medium, and labeled for identification of central memory (T(CM)) and effector memory (T(EM)) CD4⁺ T cells, and for the intracellular detection of induced CD154, IFN-γ and/or IL-2 by flow cytometry. RESULTS: Compared with CD38⁻ cells, CD38⁺ T(CM) cells from patients had less CD40L induction after CMV stimulation, and increased IFN-γ response. Patients' CD38⁺ T(EM) cells showed a lower IL-2 response, and tended to have a greater IFN-γ response, in which CD154 induction frequently failed. CMV-specific responses of patients' CD38⁺ T(CM) and T(EM) cells were dominated by IFN-γ, and almost all IL-2⁺ cells co-expressed IFN-γ. IL-2 responses to the polyclonal activator S. aureus enterotoxin B were also significantly less frequent among CD38⁺ T(CM) and T(EM) cells than in CD38⁻ cells. CONCLUSION:Patients' CD38⁺ memory CD4⁺T-cell responses to CMV favor the effector cytokine IFN-γ over IL-2, in the context of deficient CD154 induction, which may limit co-stimulation, proliferation and survival.
Authors: Janis V Giorgi; Robert H Lyles; Jose L Matud; Traci E Yamashita; John W Mellors; Lance E Hultin; Beth D Jamieson; Joseph B Margolick; Charles R Rinaldo; John P Phair; Roger Detels Journal: J Acquir Immune Defic Syndr Date: 2002-04-01 Impact factor: 3.731
Authors: N Fujita; H Kagamu; H Yoshizawa; K Itoh; H Kuriyama; N Matsumoto; T Ishiguro; J Tanaka; E Suzuki; H Hamada; F Gejyo Journal: J Immunol Date: 2001-11-15 Impact factor: 5.422
Authors: M A Ostrowski; S J Justement; L Ehler; S B Mizell; S Lui; J Mican; B D Walker; E K Thomas; R Seder; A S Fauci Journal: J Immunol Date: 2000-12-01 Impact factor: 5.422
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell Journal: J Infect Dis Date: 2013-04-04 Impact factor: 5.226
Authors: Marie R McCausland; Steven M Juchnowski; David A Zidar; Daniel R Kuritzkes; Adriana Andrade; Scott F Sieg; Michael M Lederman; Nicholas T Funderburg Journal: PLoS One Date: 2015-10-02 Impact factor: 3.240